Perhaps, adding proliferation index, as Ki-67, to the known associations between immune infiltration and subtypes may expand the knowledge of characterizing the status of host anti-tumor immune response, which needs to be taken into account in breast cancer therapeutics. This evidence concerns the gene MKI67 and breast carcinoma.